Conditions

LEDIPASVIR AND SOFOSBUVIR

Drug approval information sourced from the FDA and the PBS. Updated nightly from public government registries. Not medical advice.

Access in Australia

  • This medicine does not currently appear on the PBS Schedule, according to the Pharmaceutical Benefits Scheme. This can mean a higher out of pocket cost. Your doctor can explain the available access pathways.
  • TGA registration data for this medicine is not yet available on Voxsanity.
Updated regularly from public government registries

How it works: RNA Replicase Inhibitors

Drug class: Antivirals for treatment of HCV infections

Approval status

FDA Approved

10 October 2014
US Food and Drug Administration

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Regulatory approval does not guarantee this drug is available to you. Availability in Australia depends on PBS listing status, your specific diagnosis, your doctor's assessment, and other clinical factors.

Accessing this drug in Australia

This medicine does not currently appear on the PBS Schedule. Your doctor can explain the available access pathways, which may include the TGA Special Access Scheme ↗.

This information is drawn from publicly available PBS records. It is not medical advice. Consult your doctor about access options for your specific situation.

Approval data sourced from openFDA (CC0 licence), and the PBS schedule. Updated nightly. This page does not constitute medical advice. Drug availability and PBS listing status may change. Verify current availability and PBS coverage with your doctor or pharmacist.